Business Description
LB Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US50180M1080
Total Employee Number:
27Description
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 105.37 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -90.2 | |||||
3-Year EPS without NRI Growth Rate | -120.7 | |||||
3-Year FCF Growth Rate | -230 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -11.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.73 | |||||
9-Day RSI | 72.84 | |||||
14-Day RSI | 65.35 | |||||
3-1 Month Momentum % | 15.49 | |||||
6-1 Month Momentum % | 31.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 35.68 | |||||
Quick Ratio | 35.68 | |||||
Cash Ratio | 33.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.1 | |||||
Shareholder Yield % | -10.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -17.58 | |||||
ROA % | -14.89 | |||||
ROIC % | -396.58 | |||||
3-Year ROIIC % | -212.6 | |||||
ROC (Joel Greenblatt) % | -527.75 | |||||
ROCE % | -18.11 | |||||
Moat Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.4 | |||||
Price-to-Tangible-Book | 2.4 | |||||
EV-to-EBIT | -11.87 | |||||
EV-to-Forward-EBIT | -4.83 | |||||
EV-to-EBITDA | -11.96 | |||||
EV-to-FCF | -10.85 | |||||
| Price-to-Net-Current-Asset-Value | 2.44 | |||||
| Price-to-Net-Cash | 2.6 | |||||
Earnings Yield (Greenblatt) % | -8.42 | |||||
FCF Yield % | -5.55 |
GF Valueâ„¢
LB Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LB Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 154 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 63 days | ||
| H.C. Wainwright 7(th) Annual Neuro Perspectives Hybrid Conference | 2026-06-16 | 28.50 (-0.18%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 14:35 | 27.95 (+3.44%) | ||
| General meeting for 2026 | 2026-06-03 09:30 | 27.02 (-2.28%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 32.70 (+2.20%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-16 11:45 | 29.12 (+10.34%) | ||
| Annual report for 2025 | 2026-03-26 | 24.21 (+2.93%) |
Show
Entries
Guru Commentaries on NAS:LBRX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on LB Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers